How to find how much a company spends on R&D
By William March · Finterm
R&D spending sits on the income statement, but not every company breaks it out. Here's where to look, which us-gaap tag to use, and how to read it.
Research and development spending tells you how much a company is reinvesting in future products. For software, pharma and hardware businesses it's often the single largest operating cost after the cost of revenue — but it isn't always shown as its own line, which makes it easy to miss.
Where to look
R&D is an operating expense on the income statement, usually labelled 'Research and development' just below cost of revenue and alongside selling, general and administrative expense. In the SEC's structured data it's tagged as the us-gaap concept ResearchAndDevelopmentExpense.
When it's not broken out
Companies in capital-light or non-technical industries frequently fold R&D into a broader operating-expenses line and never report ResearchAndDevelopmentExpense at all. If a company shows no R&D figure, that's usually the reason — not that the spending is genuinely zero.
Read it as a share of revenue
The absolute dollar figure matters less than R&D intensity — R&D divided by revenue. A 20% R&D-to-revenue ratio means very different things for a mature hardware maker and an early-stage biotech, so compare a company against its own history and its direct peers, not the market as a whole.
Finterm reads ResearchAndDevelopmentExpense straight from companyfacts and puts it next to revenue per quarter, so the ratio is right there. It's a free SEC EDGAR viewer — type a ticker, no account. To pair it with the top line, see how to find a company's quarterly revenue in SEC filings.
Capitalised vs. expensed development costs
GAAP requires most R&D to be expensed as incurred. But software development costs after technological feasibility is established, and certain in-process R&D acquired in a business combination, can be capitalised. Companies that capitalise aggressively show lower R&D expense on the income statement than their actual spending on development — the rest is on the balance sheet and flows through amortisation instead. The accounting policy note in the 10-K (usually within the first few notes to the financial statements) will describe the company's policy.
What R&D intensity looks like across sectors
R&D as a percentage of revenue varies enormously by industry. Pharma and biotech: 15–30% is common; early-stage biotechs often have no product revenue and spend almost entirely on clinical trials. Enterprise software: 15–25%. Consumer tech: 10–20%. Semiconductors: 15–25% given the long cycle times. Capital-intensive industries — energy, utilities, industrials, retail — typically report under 3%, often nothing. Comparing a semiconductor company's R&D intensity to a retailer's tells you nothing; comparing it to its peers tells you a lot.